People's Finance and News, August 26—BeiGene announced that on August 26, the U.S. Food and Drug Administration (FDA) has approved the supplementary Biologics License Application (sBLA) for Bazean? (terelentuzumab, formerly known as telituximab). The approval is for a new indication: first-line treatment in adult patients with locally advanced unresectable or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA, referred to as “gastroesophageal adenocarcinoma”), in combination with Beihaian? (zenidatamab, formerly known as zetontamab) and chemotherapy.